Wustman; Brandon

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wustman; Brandon.The latest application filed is for "treatment of primary ciliary dyskinesia with synthetic messenger rna".

Company Profile

2.12.18

Wustman; Brandon - San Diego CA
Wustman; Brandon - Princeton NJ US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment Of Primary Ciliary Dyskinesia With Synthetic Messenger Rna App 20220211873 - Lockhart; David J. ; et al.	2022-07-07
Method to predict response to pharmacological chaperone treatment of diseases Grant RE48,608 - Benjamin , et al. June 29, 2	2021-06-29
Treatment Of Primary Ciliary Dyskinesia With Synthetic Messenger Rna App 20210162068 - Lockhart; David J. ; et al.	2021-06-03
Treatment Of Primary Ciliary Dyskinesia With Synthetic Messenger Rna App 20190117796 - Lockhart; David J. ; et al.	2019-04-25
Treatment Of Primary Ciliary Dyskinesia With Synthetic Messenger Rna App 20190111074 - Lockhart; David J. ; et al.	2019-04-18
Method to predict response to pharmacological chaperone treatment of diseases Grant 9,545,397 - Benjamin , et al. January 17, 2	2017-01-17
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases App 20170003301 - BENJAMIN; Elfrida ; et al.	2017-01-05
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones App 20150352093 - Lockhart; David ; et al.	2015-12-10
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases App 20150342940 - BENJAMIN; Elfrida ; et al.	2015-12-03
Method to predict response to pharmacological chaperone treatment of diseases Grant 9,095,584 - Benjamin , et al. August 4, 2	2015-08-04
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Grant 9,056,101 - Lockhart , et al. June 16, 2	2015-06-16
Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases Grant 9,044,437 - Wustman , et al. June 2, 2	2015-06-02
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes Grant 8,883,813 - Wustman November 11, 2	2014-11-11
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases App 20140206721 - Benjamin; Elfrida ; et al.	2014-07-24
Method to predict response to pharmacological chaperone treatment of diseases Grant 8,592,362 - Benjamin , et al. November 26, 2	2013-11-26
Method Of Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase Presenilin Function And Gamma-secretase Activity App 20130102538 - Wustman; Brandon ; et al.	2013-04-25
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases App 20120309788 - Wustman; Brandon ; et al.	2012-12-06
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases App 20110212996 - Benjamin; Elfrida ; et al.	2011-09-01
TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS App 20110189710 - Wustman; Brandon ; et al.	2011-08-04
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases App 20110152319 - Benjamin; Elfrida ; et al.	2011-06-23
Methods for treating parkinsons disease and parkinsonism Grant 7,964,617 - Wustman June 21, 2	2011-06-21
Assays For Diagnosing And Evaluating Treatment Options For Pompe Disease App 20110136151 - Wustman; Brandon ; et al.	2011-06-09
Treatment Of Cns Disorders Associated With Mutations In Genes Encoding Lysosomal Enzymes App 20110105560 - Wustman; Brandon	2011-05-05
Dosing Regimens For The Treatment Of Lysosomal Storage Diseases Using Pharmacological Chaperones App 20100266571 - Lockhart; David ; et al.	2010-10-21
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes App 20060287358 - Wustman; Brandon	2006-12-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.